Drug Development & Prescription Principles — General Pharmacology

Drug Development & Prescription Principles MCQs: practice questions

Sample Drug Development & Prescription Principles multiple-choice questions from General Pharmacology.

1. A patient has difficulty swallowing tablets. Which prescribing principle is most appropriate?

   • A. Ignore adherence
   • B. Always prescribe an extended-release tablet
   • C. Increase the dose automatically
   • D. Select a suitable formulation and route
   • E. Use intravenous therapy for every medication

2. A clinician is choosing between two drugs with similar efficacy. One has substantially fewer clinically important adverse effects for the patient's comorbidities. Which principle favors the second drug?

   • A. Always choosing the cheapest drug regardless of risk
   • B. Always choosing the newest drug
   • C. Select the safer effective drug
   • D. Choosing the most potent drug
   • E. Ignoring comorbidities

3. A clinical trial reports a statistically significant difference between treatment groups. What additional issue must be considered before changing practice?

   • A. Only the p-value
   • B. Only the route of administration
   • C. Only the drug's brand name
   • D. Only the sample's average age
   • E. Clinical relevance and safety

4. Which phase primarily evaluates efficacy and dose-response in patients with the target disease?

   • A. Phase IV
   • B. Phase I
   • C. Phase III
   • D. Phase II
   • E. Postmarketing surveillance only

5. A large randomized trial compares a new drug with standard therapy before regulatory approval. This is most characteristic of:

   • A. Phase I
   • B. Phase III
   • C. Phase II
   • D. Phase IV
   • E. Case report

6. A patient has stable hepatic failure and is prescribed a drug extensively metabolized by the liver. What prescribing consideration is most important?

7. A physician prescribes an antibiotic for a confirmed bacterial infection after considering allergies, renal function, interactions, and local susceptibility data. This best illustrates:

8. Which information is most important before selecting a drug for a patient with chronic kidney disease?

9. A generic drug is expected to have which relationship to its branded counterpart?

10. A clinician wants to know whether a patient's plasma concentration is within a therapeutic range. Which tool is most appropriate?

11. A clinician chooses a medication after considering diagnosis, contraindications, interactions, patient factors, and evidence. This is an example of:

12. Which outcome is a primary concern during early human drug testing?

13. A medication is already approved and clinicians continue to collect information about rare adverse effects. This is:

14. A clinician wants to determine whether a new drug is superior to placebo in reducing a clinical outcome. Which study design is most appropriate?

15. A randomized controlled trial is best designed to reduce which major source of bias?

16. Which factor is especially important when prescribing a drug with a narrow therapeutic index?

17. A medication's approval is followed by continued collection of adverse-event reports. This process is especially valuable for detecting:

18. A medication is available as immediate-release and extended-release formulations. The extended-release form is most useful when the goal is to:

19. A physician reviews a patient's complete medication list before prescribing a new drug. The primary purpose is to identify:

20. Which statement about a prescription is most consistent with rational drug use?

21. Blinding in a clinical trial primarily reduces bias related to:

22. A postmarketing report identifies a rare adverse effect occurring in 1 of 20,000 treated patients. Why might it not have been detected before approval?

23. Therapeutic drug monitoring is particularly useful for drugs that have:

24. A patient asks why a physician selected a generic medication rather than the brand-name product. The most appropriate general explanation is that the generic:

25. A study compares disease outcomes between exposed and unexposed groups without assigning treatment. This is an example of:

26. A prescription is being written for a medication with a very narrow therapeutic window. Which approach is most appropriate?

27. Which phase of a clinical trial is primarily designed to assess safety and pharmacokinetics in a small number of healthy volunteers?

28. Which clinical trial design provides the strongest protection against confounding when comparing two treatments?

29. A patient is prescribed a medication with a dosing schedule requiring multiple daily doses. Which prescribing strategy may improve adherence when clinically appropriate?

30. Which principle best supports choosing the lowest effective dose of a medication?